i believe the problem is not with the phase2 trials with sham/placebo surgery but with the way the phase1 open label trials are run. maybe their results should be questioned, not phase2. there's speculation that results are so good in phase1 because participants are so hopeful and huge placebo affect and the main researcher is involved and might be a little biased.

bigger problem is they have to be better than a dbs, not easy.